Clinical features and outcomes of patients with anti-neutrophil cytoplasmic antibody-positive systemic lupus erythematosus from a single-center retrospective study - Scorecard - MDSpire
Advertisement
Clinical features and outcomes of patients with anti-neutrophil cytoplasmic antibody-positive systemic lupus erythematosus from a single-center retrospective study
Clinical Scorecard: Clinical Characteristics and Outcomes in Patients with Anti-Neutrophil Cytoplasmic Antibody-Positive Systemic Lupus Erythematosus: Insights from a Retrospective Study at a Single Center
At a Glance
Category
Detail
Condition
Systemic lupus erythematosus (SLE)
Key Mechanisms
Presence of specific autoantibodies such as anti-dsDNA and ANCA associated with disease manifestations.
Target Population
Patients diagnosed with SLE, particularly those with ANCA positivity.
Care Setting
Retrospective analysis in a university hospital setting.
Key Highlights
Anti-dsDNA antibodies are associated with lupus nephritis (LN).
Overlap between SLE and ANCA-associated vasculitis (AAV) is linked to severe disease phenotypes.
9.3% of SLE patients were positive for anti-MPO antibodies.
High mortality rate associated with the coexistence of SLE and AAV.
Guideline-Based Recommendations
Diagnosis
Use 2019 EULAR/ACR classification criteria for SLE diagnosis.
Confirm ANCA positivity with ELISA for anti-MPO or anti-PR3 antibodies.
Management
Aggressive immunosuppressive therapy with high-dose glucocorticoids and cyclophosphamide for severe cases.
Monitoring & Follow-up
Regular assessment of clinical manifestations and laboratory findings.
Risks
Increased risk of serious manifestations such as rapidly progressive glomerulonephritis.
Patient & Prescribing Data
Polish cohort of SLE patients with ANCA positivity.
Therapeutic approaches include immunosuppressive treatments tailored to disease severity.
Clinical Best Practices
Recognize antibody–phenotype associations for accurate diagnosis.
Consider alternative causes of vasculitis in SLE patients.
The procedure was performed under a HOPE Act research protocol at an NYU Langone Health center the institution said is among the limited number of US transplant centers equipped and approved to perform HOPE lung transplants.
